I don't think that a discussion of off-label drug use has done the rounds recently. Going back to a couple of my old posts from January 2015 for easy-to-find-research;
'According to one source, more than one in five outpatient prescriptions written in the US are for off-label therapies. The FDA regulates drug approval but doctors prescribe drug use,' and
'Off-label drug use (OLDU) may even be considered integral to public health. OLDU occurs in virtually every therapeutic area and is relatively common in pediatrics as well as elderly populations. Once approved, it is generally accepted that physicians may prescribe drugs for any therapeutic use which is considered appropriate in their medical judgement. The use of OLDU may highlight conditions which warrant supplementary clinical trials'.
Once Trofinetide is approved for Retts, particularly given its safety profile, could it be prescribed for instance in elderly populations for conditions such as dementia and Alzheimer disease?
- Forums
- ASX - By Stock
- NEU
- Reasons for consideration
Reasons for consideration, page-96
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3816 | $13.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.78 | 2834 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 13.620 |
2 | 733 | 13.510 |
7 | 9120 | 13.500 |
1 | 1000 | 13.480 |
1 | 50 | 13.420 |
Price($) | Vol. | No. |
---|---|---|
13.960 | 2652 | 1 |
14.000 | 6595 | 2 |
14.110 | 1000 | 1 |
14.120 | 493 | 1 |
14.250 | 1000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online